The primary goal of this study was to determine the median effective dose (ED 50 ) of spinal chloroprocaine for labour analgesia. Thirty-eight parturients requesting neuraxial analgesia were enrolled. Doses of 1% chloroprocaine were determined by the technique of up-down sequential allocation, with an initial dose of 20 mg and steps of 2 mg. The chloroprocaine spinal dose was given as the spinal component of a combined spinal-epidural, which was then supplemented with an epidural dose of 7.5 lg sufentanil in 7 ml saline. Effective analgesia was defined as a score ≤ 10 mm within 15 min on a 100-mm visual analogue pain scale. Using the isotonic regression estimator method, the ED 50 of chloroprocaine for the spinal component of a combined spinal-epidural for labour was calculated to be median (95%CI) 12.0 (9.3-17.0) mg.
Introduction
Combined spinal-epidural (CSE) analgesia for labour is a widely-accepted technique because of several advantages such as a fast onset of analgesia, reliable anaesthesia of the sacral roots, less need for oxytocin augmentation or instrumental vaginal delivery, and low maternal and fetal drug concentrations [1] . Despite the widespread use of this technique and numerous published investigations, an optimal spinal drug regimen has not yet been defined.
Bupivacaine, ropivacaine or levobupivacaine are normally used for the spinal component of CSE during labour. Chloroprocaine has recently been re-introduced into clinical practice. It is an amino-ester local anaesthetic, known for a very quick onset of action of 2-3 min when given epidurally, and with high efficacy. It is rapidly hydrolysed by plasma cholinesterases, resulting in a short half-life in both mother and fetus [2] . Since chloroprocaine was first introduced into clinical practice in 1952, it has been used extensively for epidural anaesthesia and peripheral blocks [3] . Reports in the early 1980s of transient neurological symptoms associated with possible accidental spinal injection of epidural chloroprocaine raised concerns regarding potential neurotoxicity [4] . Review of these reports suggested that the neurological injuries resulted from large volumes of chloroprocaine injected into the spinal space, the acidity of the solution and the relative toxicity of bisulphite used as an antioxidant [5] . Since 1996, chloroprocaine has been produced without bisulphite. Although not specifically indicated for spinal use, preservative-and antioxidant-free chloroprocaine has been investigated for spinal anaesthesia in ambulatory surgical patients over a number of years [2, 6] , and large series of spinal anaesthetics with chloroprocaine without major peri-operative neurological injury have been published [7] . In fact, Casati et al. demonstrated a 33% incidence of transient neurological symptoms after spinal lidocaine compared with none after chloroprocaine [8] . After consideration of these arguments, the spinal use of preservative-free chloroprocaine was approved in Europe [7, 9] .
In obstetric anaesthesia in the 1990s, chloroprocaine was primarily used for epidural analgesia during labour [10] . Ackerman et al. advised the use of chloroprocaine for its rapid onset when topping-up an epidural for instrumental delivery (the 'perineal dose') [11] . Chloroprocaine might be beneficial if the fetus is compromised because of rapid hydrolysis in blood [12] . Abboud et al. reported less late decelerations of fetal heart rate with epidural chloroprocaine versus bupivacaine [13] . Because of this beneficial therapeutic profile, more recent studies have focused on spinal or epidural use of chloroprocaine at caesarean section [14, 15] .
Based on this, we considered that chloroprocaine would be a suitable drug for CSE labour analgesia. The minimum local anaesthetic concentration of epidural chloroprocaine in labour is 0.42% w/v [16] , but no data on the correct dose exist for spinal administration.
The primary aim of this study was to determine the median effective dose (ED 50 ) of spinal chloroprocaine 1% for CSE analgesia during labour, using an up-down sequential allocation method.
Methods
Ethical approval for this study was provided by the Ethical Committee of Ghent University Hospital. We recruited ASA physical status 1-2 women in active labour requesting neuraxial analgesia, who were aged between 18-45 years with a singleton fetus at 36-41 weeks gestation. Women were not recruited if they had received opioid or sedative medication, had a cervical dilation > 7 cm, pre-eclampsia, sensory or motor deficits in the lower body, fetal congenital abnormalities, or a known allergy to chloroprocaine.
Written informed consent was obtained at the earliest opportunity after the parturient was admitted to the labour ward. After requesting regional analgesia, baseline heart rate, blood pressure and oxygen saturation were recorded, and continuous monitoring of fetal heart rate and uterine contractions was established. After an intravenous infusion of Hartmann's solution was started, CSE was performed with the women in the sitting position. After skin disinfection and infiltration with lidocaine 1%, the epidural space was identified using loss-of-resistance to saline at the L3-4 or L4-5 intervertebral space with an 18-G Tuohy needle. A 27 G, 127 mm Whitacre spinal needle was then introduced through the Tuohy needle until cerebrospinal fluid was obtained. The end of the spinal injection of chloroprocaine was defined as the start time of the study. Subsequently, the spinal needle was withdrawn and an epidural volume extension bolus of 7.5 lg sufentanil in 7 ml saline was injected [17] [18] [19] . An epidural catheter was inserted 4-5 cm into the epidural space, and after fixation of the epidural catheter, the women were placed in a 45°head-up position with left uterine displacement. A patient-controlled epidural analgesia regimen, containing 112 ml levobupivacaine 1.1 mg.ml À1 and 0.7 lg.ml À1 sufentanil, was started 30 min after the spinal bolus of chloroprocaine. We found no guidelines for the dose of chloroprocaine for labour spinal analgesia in the literature. Lowdose spinal anaesthesia for caesarean section is often performed with 7.5 mg bupivacaine, although the ED 95 of bupivacaine with 10 lg fentanyl is 13 mg [20] , while the ED 95 for spinal bupivacaine in labour analgesia is 3.3 mg [21] . For ambulatory surgery, Lacasse et al. showed that 40 mg spinal chloroprocaine provides adequate duration and depth of surgical anaesthesia for short procedures [22] . We therefore chose to start the sequential allocation with a reduced dose of 20 mg chloroprocaine 1%. After this, the dose of chloroprocaine received by a particular patient was determined by the analgesic response of the previous patient. This resulted in the administration of either a higher or a lower dose of chloroprocaine, according to an up-down sequential allocation design, using 2-mg increments or decrements. Analgesic effectiveness was assessed using a 100-mm visual analogue pain score (VAPS), where 0 represented 'no pain' and 100 indicated 'worst pain possible'. The VAPS was measured at 5-min intervals for 30 min after spinal injection. Effective analgesia was defined as VAPS ≤ 10 mm, 15 min after the spinal injection. Women with ineffective analgesia after 15 min received 12 ml levobupivacaine 0.125% via the epidural as a rescue dose.
Further data collected at 5-min intervals included sensory block level and the degree of motor block. Sensory level was determined by loss of cold sensation to ethyl chloride spray. Motor block was determined using a modified Bromage scale, where 1 = complete motor block, unable to move legs; 2 = only possible to move feet; 3 = possible to move knees; 4 = weak flexion of hips; and 5 = complete flexion of hips and knees. Additionally, maternal heart rate, blood pressure and oxygen saturation, and fetal heart rate and contraction frequency, were monitored during the next 3 h.
The up-down sequences were analysed using the isotonic regression estimator method [23] [24] [25] , from which we calculated ED 50 , ED 95 and 95%CI. Calculations were performed using R software (R 3.0.1. for Windows; R Foundation for Statistical Computing, Vienna, Austria).
Results
Of the 40 women enrolled, two were not studied. One woman received the wrong dose of chloroprocaine, and another received systemic opioid before the CSE. In these cases, the intended dose was used for the next woman who was enrolled. In total, 38 parturients were included in the analysis. Their characteristics are shown in Table 1 . Figure 1 shows the up-down sequence by case. Using the isotonic regression estimator method, the ED 50 (95%CI) was calculated to be 12.0 (9.3-17.0) mg, and ED 95 (95%CI) was estimated as 19.6 (16.0-20.0) mg.
Discussion
This is the first study to determine the ED 50 of spinal chloroprocaine in the first stage of labour as part of a CSE. We used an up-down sequential allocation method, which has greater precision and requires fewer subjects than traditional dose-response studies. The ED 50 provides a value to compare the potency of chloroprocaine with other local anaesthetics currently used for labour analgesia. ED 50 values estimated through an up-down sequential allocation method only represent a single point along the dose-response curve, but do not show the steepness of the curve [26] . In clinical practice, the ED 95 may be more important.
ED 50 and ED 95 values for spinal analgesia during labour for commonly used local anaesthetics have been determined; these are median (95%CI) 1.7 (1.4-1.9) mg and 3.3 (2.9-4.1) mg for bupivacaine, 2.2 (1.8-2.6) mg and 4.8 (4.0-6.7) mg for ropivacaine and 2.3 (2.0-2.7) mg and 5.0 (4.1-7.0) mg for levobupivacaine, respectively [21] . We found that the ED 50 of chloroprocaine is 12.0 (9.3-17.0) mg, with a calculated ED 95 of 19.6 (16.0-20.0) mg. However, a study using a biased coin design would be necessary to produce a more reliable result for the ED 95 [23, 25, 26] .
There are some limitations to our study. One problem with the up-down sequential allocation [27, 28] . In our study, only patients with cervical dilation ≤ 7 cm were accepted for inclusion. However, we did not distinguish between spontaneous labour and prostaglandin-induced labour, or nulliparous and multiparous women. We also cannot exclude a possible influence of sufentanil, administered epidurally, on our reported ED 50 of spinal chloroprocaine. We routinely use epidural sufentanil immediately following spinal analgesia in our unit, in order to reduce the incidence of fetal heart rate abnormalities found with opioid given spinally [17] , and we designed this study to reflect our clinical practice as much as possible. However, we suggest that, with the low dose of epidural sufentanil that we used, there would have been minimal effect at the 15-min assessment time [28] .
Finally, there was no blinding of the investigator, who also performed the CSE. However, the parturient did not know what dose of chloroprocaine they received, and, as a consequence, their reporting of the analgesic effect was unbiased.
The beneficial pharmacokinetic characteristics of chloroprocaine explain the renewed interest in its use in obstetric anaesthesia. Rapid hydrolysis by plasma cholinesterases guarantees a short half-life both in mother and fetus, with low risk of systemic side-effects. We have calculated an ED 50 of median (95%CI) 12.0 (9.3-17.0) mg for spinal chloroprocaine as part of CSE labour analgesia. Further studies are necessary to determinate the full dose-response curve for spinal chloroprocaine.
